 |
 |
 |
 |
 |
>We are exploring apoptosis induced in B cell lines by antineoplastic drugs.
> We suspect that induction of FAS ligand may play a role with one or more
>drugs. Antibodies to FAS-L exist and an Fc fragment that inhibits binding
of
>FAS-L to the FAS receptor is also now available. My question is this: is
it
>enough to establish the FAS link by demonstrating a reduction in apoptosis
>with either of these agents (the anti-FASL antibody or the Fc fragment) or
is
>it necessary to use both?
I would suggest the following course of experiments:
-determine whether the cell line in question expresses FasR and what happens
to the levels upon drug treatment
-attempt to induce apoptosis in the cells with an inducing anti Fas Ab or
souluble Fas L in th e presence or absence of drug
-then attempt to block this interaction with either or both of the reagent s
you mentioned
-remember that , depending on the specific system,modulatin of many other
molecules [both pro and anti apoptotic] may be involved in inducing or
preventing cell death
Good luck,
Tom
--------------------------------------------------------
Thomas W. Mc Closkey, Ph. D.
Director, Flow Cytometry
North Shore University Hospital
Biomedical Research Center
350 Community Drive
Manhasset, Long Island, New York 11030
ph: 516-562-4844 [office]; 516-562-1135/4641 [lab]
4/1/97 12:45:41 PM
E-mail: thomasm@nshs.edu
--------------------------------------------------------
|
|
|
|
|
|
CD-ROM Vol 3 was produced by Monica M. Shively and other staff at the
Purdue University Cytometry Laboratories and distributed free of charge
as an educational service to the cytometry community.
If you have any comments please direct them to
Dr. J. Paul Robinson, Professor & Director,
PUCL, Purdue University, West Lafayette, IN 47907.
Phone: (765)-494-0757;
FAX(765) 494-0517;
Web